Turning Point Therapeutics, Inc.
If you purchased Turning Point Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
TPTX STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF TURNING POINT THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS
June 3, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Turning Point Therapeutics, Inc. (NASDAQ: TPTX) to Bristol Myers Squibb for $76.00 per share is fair to Turning Point shareholders.
The investigation concerns whether Turning Point and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Turning Point shareholders; (2) determine whether Bristol Myers is underpaying for Turning Point; and (3) disclose all material information necessary for Turning Point shareholders to adequately assess and value the merger consideration. On behalf of Turning Point shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.